VEGFA and interstitial lung disease: Clinical studies has shown that nintedanib, a multi-targeted TKI of VEGF, PDGF, and FGF, is effective in reducing the decline of forced vital capacity in patients with progressive fibrosing ILD and decreasing the events of ILD progression (67–69).